SL
UTHR icon

Salomon & Ludwin’s United Therapeutics UTHR Stock Holding History

Salomon & Ludwin’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$547 Hold
1
– – ﹤0.01% 2056
2026
Q1 		$565 Sell
1
-25
-96% -$12.4K ﹤0.01% 2037
2025
Q4 		$12.7K Buy
26
+25
+2,500% +$11.6K ﹤0.01% 1274
2025
Q3 		$453 Buy
+1
New +$336 ﹤0.01% 2094

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Salomon & Ludwin's UTHR Position: Q2 2026 in Review

Salomon & Ludwin held its United Therapeutics (UTHR) position steady in Q2 2026 at 1 share worth $547. The position accounts for ﹤0.01% of the portfolio, ranked #2056.

Salomon & Ludwin first reported a position in UTHR in Q3 2025 and has held it in 4 quarters since. The position peaked at $12.7K in Q4 2025. 874 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Salomon & Ludwin held 1 share of United Therapeutics worth $547 as of Q2 2026.
  • Salomon & Ludwin left its United Therapeutics share count unchanged in Q2 2026.
  • United Therapeutics made up ﹤0.01% of Salomon & Ludwin's portfolio in Q2 2026, its #2056 holding.
  • Salomon & Ludwin first reported a position in United Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Salomon & Ludwin's United Therapeutics position peaked at $12.7K in Q4 2025.
  • 874 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Salomon & Ludwin's 13F filing for Q2 2026, filed 7 Aug 2026.